Bioage prepares for IPO, targets obesity with new drug trials
FierceBiotech - 04-Sep-2024Biotech firm Bioage plans public debut as it advances promising obesity treatments
Join the club for FREE to access the whole archive and other member benefits.
Developing a broad pipeline of therapies to extend human healthspan and lifespan
We’re an interdisciplinary team of computational biologists, experimental scientists, and seasoned drug hunters. We share the vision that targeting aging directly, rather than targeting individual age-related diseases one at a time, will have a dramatic positive impact on human health.
The BIOAGE discovery platform leverages recent technological advances to create a deep omics map of human aging. We generate this map by applying novel machine learning and bioinformatics approaches to proprietary human cohort data to reveal the molecular drivers of age-related pathology. Our pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.
At BIOAGE, we are mapping human aging from the ground up. We have forged partnerships with unique biobanks containing healthy human samples collected over decades that are paired with extensive follow-up records that include detailed future healthspan, lifespan, and disease outcomes. We are building deep molecular profiles of these samples, incorporating proteomics, metabolomics, and transcriptomics to identify the best drug targets for healthy aging.
Visit website: https://bioagelabs.com/
Details last updated 28-Feb-2020
Professor of Medicine, Department of Medicine Division of Endocrinology, Diabetes and Nutrition, Brigham and Women's Hospital
31-Aug-2021 to 03-Sep-2021
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
BBC Click meets biohackers and companies who believe it will be possible to live on to well beyond 100
Biotech firm Bioage plans public debut as it advances promising obesity treatments
Their main drug, azelaprag, is like a pill that mimics the benefits of exercise
Another reminder of the amount of research, with multiple approaches, about to go into clinical trials
Had success in reducing muscle atrophy and discovered novel class of molecules to target cognitive decline
They aim to identify aging pathways and develop new drugs and biomarkers
Raised $90M in series C funding - off to a great start initiating three clinical trials
Reverses immune ageing and can prevent death from coronavirus infection in the elderly
Lead therapies of BioAge to treat age related diseases enter phase 2 trials
I think Victor is right, anti-aging is going to be the next big thing